Pulmonary arterial hypertension: A flavor of autoimmunity;Hypertension artérielle pulmonaire: Un parfum d'auto-immunité

Medecine/Sciences

Volumn 29, Issue 6-7, 2013, Pages 607-616

  Perros, Frédéric ^a,b,c   Humbert, Marc ^a,b,c   Cohen Kaminsky, Sylvia ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6 RECEPTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PULMONARY HYPERTENSION; REVIEW;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; HYPERTENSION, PULMONARY; IMMUNOTHERAPY; RECEPTORS, INTERLEUKIN-6;

EID: 84880849903     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2013296013     Document Type: Review

References (57)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34 : 1219-63.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351 : 1425-36.
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 : S43-54.
4. Girerd B, Montani D, Eyries M, et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010; 11 : 73.
5. O'Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011; 8 : 526-38.
6. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122 : 156-63.
7. Perros F, Montani D, Dorfmuller P, et al. Nouvelles approches immunopathologiques de l'HTAP. Presse Med 2011 ; 40 Suppl 1 : 1S3-13.
8. Tamby MC, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005; 60 : 765-72.
9. Terrier B, Tamby MC, Camoin L, et al. Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 2010; 69 : 428-33.
10. Terrier B, Tamby MC, Camoin L, et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177 : 1128-34.
11. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008 ; 58 : 521-31.
12. Pugh ME, Hemnes AR. Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond Engl) 2010; 6 : 285-96.
13. Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, et al. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun 2012 ; 38 : J109-19.
14. Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 186 : 892-6.
15. Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010; 56 : 696-708.
16. Nicolls MR, Taraseviciene-Stewart L, Rai PR, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005 ; 26 : 1110-8.
17. Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 185 : 311-21.
18. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a french nationwide prospective multicenter study. Arthritis Rheum 2005 ; 52 : 3792-800.
19. Fois E, Le Guern V, Dupuy A, et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol 2010 ; 28 : 836-41.
20. Chu JW, Kao PN, Faul JL, et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002; 122 : 1668-73.
21. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008 ; 177 : 108-13.
22. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009 ; 119 : 1518-23.
23. Austin ED, Rock MT, Mosse CA, et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med 2010 ; 104 : 454-62.
24. Ulrich S, Nicolls MR, Taraseviciene L, et al. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 2008 ; 75 : 272-80.
25. Huertas A, Tu L, Gambaryan N, et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J 2012 ; 40 : 895-904.
26. Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 186 : 897-908.
27. Tamosiuniene R, Tian W, Dhillon G, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 2011 ; 109 : 867-79.
28. Perros F, Cohen-Kaminsky S, Humbert M. Understanding the role of CD4+CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension. Respiration 2008; 75 : 253-6.
29. Karmochkine M, Cacoub P, Dorent R, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996 ; 23 : 286-90.
30. Riboldi P, Gerosa M, Raschi E, et al. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003; 207 : 29-36.
31. Bussone G, Tamby MC, Calzas C, et al. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis 2012 ; 71 : 596-605.
32. Renaudineau Y, Dugue C, Dueymes M, et al. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002 ; 1 : 365-72.
33. Negi VS, Tripathy NK, Misra R, et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998 ; 25 : 462-6.
34. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995 ; 151 : 1628-31.
35. Farha S, Sharp J, Asosingh K, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ 2012 ; 2 : 220-8.
36. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature 2002; 420 : 875-8.
37. Arends SJ, Damoiseaux J, Duijvestijn A, et al. Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension. Eur Respir J 2010 ; 35 : 923-5.
38. Rose NR, Bona C Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14 : 426-30.
39. Yeager M, Cripe PJ, Colvin KL, et al. Loss of tolerance associated with bronchus associated lymphoid tissue expansion in pulmonary hypertension. Am J Respir Crit Care Med 2012 ; 185 : A4761.
40. Quismorio FP Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13 : 349-59.
41. Carragher DM, Rangel-Moreno J, Randall TD. Ectopic lymphoid tissues and local immunity. Semin Immun 2008; 20 : 26-42.
42. Price LC, Montani D, Tcherakian C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 2011 ; 37 : 813-22.
43. Ogawa A, Nakamura K, Mizoguchi H, et al. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011 ; 183 : 139-40.
44. Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus 2008; 17 : 754-6.
45. Semerano L, Boissier MC. Les anticorps monoclonaux dans les maladies immunes inflammatoires chroniques. Med Sci (Paris) 2009; 25 : 1108-12.
46. Tanaka Y. Diagnosis and therapy for systemic lupus erythematosus. Nihon Naika Gakkai Zasshi 2007; 96 : 2159-64.
47. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005 ; 52 : 501-13.
48. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012; 33 : 571-7.
49. Kishimoto T. Interleukin-6 and its receptor in autoimmunity. J Autoimmun 1992 ; 5 Suppl A : 123-32.
50. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circulation Res 2009; 104 : 236-44.
51. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010 ; 122 : 920-7.
52. Karavolias GK, Georgiadou P, Gkouziouta A, et al. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Expert Opin Ther Targets 2010 ; 14 : 1283-9.
53. Furuya Y, Satoh T, Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol 2010 ; 2010 : 720305.
54. Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. Heart Vessels 2010 ; 25 : 444-7.
55. Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. Int J Hematol 2009 ; 90 : 99-102.
56. Terrier B, Mouthon L. Lupus erythemateux systemique. Med Sci (Paris) 2013; 29 : 65-73.
57. Cartron G, Rossi JF. Anticorps monoclonaux therapeutiques en oncohematologie. Med Sci (Paris) 2009; 25 : 1085-9.